Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

11 Feb 2016 - 12 Feb 2016
18 Feb 2016 - 20 Feb 2016
25 Feb 2016 - 26 Feb 2016

Lung Biopsies Reduced by Panel of Serum Biomarkers

By Labmedica International staff writers
Posted on 04 Apr 2012
Print article
A panel of serum biomarkers could help predict the level of lung cancer risk in high-risk patients, offering doctors an option before proceeding with a biopsy.

The panel of protein biomarkers could help in lung cancer diagnosis as given the substantial risks of invasive diagnostic thoracic procedures, and unselective biopsy of every person with a small nodule is clinically undesirable.

A multicenter team, led by scientists at the University of Pittsburgh Cancer Institute (PA, USA), identified candidate serum biomarkers in a training set of sera from 56 patients with biopsy-proven primary non-small-cell lung cancer and 56 age-, sex-, and smoking-matched controls. They measured 70 cancer-related proteins by Luminex xMAP multiplexed immunoassays. The classification performance of the 10-biomarker panel was also analytically validated using enzyme-linked immunosorbent assays (ELISA) in a second independent case/control population, further validating the robustness of the panel.

The scientists identified a panel of 10 serum biomarkers including prolactin, transthyretin, thrombospondin-1, E-selectin, C-C motif chemokine 5, macrophage migration inhibitory factor, plasminogen activator inhibitor, receptor tyrosine-protein kinase, cytokeratin fragment 21.1, and serum amyloid A, which distinguished lung cancer patients from controls. The xMAP-multiplexed immunoassays are products of Luminex (Austin, TX, USA).

The ELISA kits for human thrombospondin-1, plasminogen activator inhibitor (PAI-1 and SERPINE1), and macrophage migration inhibitory factor (MIF), are products of R&D Systems (Minneapolis, MN, USA). ELISA kits for carcinoembryonic antigen (CEA), receptor tyrosine-protein kinase 2, and transthyretin (TTR) are manufactured by Immunology Consultants Laboratory, (Minneapolis, MN, USA), Calbiochem (Gibbstown, NJ, USA), and ALPCO (Salem, NH, USA), respectively.

The authors concluded that although the biomarker model they described could not detect every lung cancer, it offers a significant clinical improvement over computed tomography (CT) imaging alone. According to the study, about 20% of the 1-2 cm nodules that are concerning enough to be considered for biopsy are actually malignant, but those who are identified by small pulmonary nodules can be correctly classified by the study's model. The article was published in the April 2012 issue of the Journal of Thoracic Oncology.

Related Links:

University of Pittsburgh Cancer Institute
Luminex
R&D Systems




Print article
Micromedic Technologies

Channels

Immunology

view channel
Image: Micrograph of prostatic adenocarcinoma with perineural invasion, conventional (acinar) type, the most common form of prostate cancer. Prostate biopsy, H&E stain (Photo courtesy of Nephron and Wikimedia).

Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. The number of prostate needle biopsies (PNB) has been reduced and... Read more

Industry News

view channel
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).

Collaboration Helps Accelerate Launch of New Malaria Test

The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.